LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MGI Launches New Gene Sequencing Platforms at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: The new NBSEQ-G99 gene sequencer with mid to low range throughput (Photo courtesy of MGI)
Image: The new NBSEQ-G99 gene sequencer with mid to low range throughput (Photo courtesy of MGI)

MGI Tech Co. Ltd. (Shenzhen, China) is introducing its latest gene sequencing platforms at Medlab Middle East 2023, taking place 6-9 February in Dubai. The three new products being launched at Medlab Middle East by MGI includes DNBSEQ-G99, its latest gene sequencer with a mid to low range throughput, DNBSEQ-E25, a portable sequencer with a very low throughput, the DNBelab-D4 digital sample preparation system. In addition, the company is also displaying its MGISP-100 automated sample preparation system for visitors at its booth.

As one of the sequencers with the fastest speed among those with the same throughput in the world, DNBSEQ-G99 is based on MGI's core DNBSEQTM sequencing technology. It is the first sequencer to adopt triangular matrix signal spots on sequencing flow cell, among other innovations in biochemistry, optics, fluidics, temperature control and more, reaching higher density of data output, with an overall throughput of 8-48 Gb per run. DNBSEQ-G99 is especially suitable for targeted gene sequencing and small genome sequencing, requiring only 12 hours to finish PE150 sequencing.

DNBSEQ-E25, the flagship product in the E-series, is a portable, accessible, and user-friendly sequencer that features a data throughput of up to 7.5G daily. Built on the newly designed self-luminous biochemical system, DNBSEQ-E25 has upgraded its sequencing system, flowcells and sequencing cartridge. Equipped with built-in bioinformatics, it is designed to run sequencing and generate analysis reports on the go. Its ease of setup means it is ready to run in ten minutes, coupled by a quick turnaround time that takes only 20 hours from sample to FASTQ data.

Lastly, DNBelab-D4 is the first digital microfluidic automation platform developed by MGI. The portable digital sample preparation system can prepare samples from DNA to DNB on a single sample prep card. Meanwhile, it integrates the quantification function for automatic quantification after DNB preparation is completed, eliminating the need for manual quantification. Currently, DNBelab-D4 is mainly used for library preparation for high-throughput sequencing applications such as metagenomics sequencing of unknown pathogens. It can also cater to the requirements of different research and medical applications.

"We are excited to launch three new products at MEDLAB Middle East, including DNBSEQ-G99, our latest model of gene sequencer with mid to low range throughput, DNBSEQ-E25, a portable sequencer with very low throughput, as well as DNBelab-D4 digital sample preparation system. In addition, our MGISP-100 automated sample preparation system will be on display for visitors interested to learn more," said Dr. Roy Tan, General Manager of MGI Asia Pacific. "Once again, MGI showcases the commitment to supporting healthcare, scientific research and applications across the Middle East through our genomic technologies."

Related Links:
MGI Tech Co. Ltd.

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.